IL-1R与NFKBIZ通路介导间变性大细胞淋巴瘤的免疫调节反应及免疫治疗疗效
研究通过全基因组CRISPR-Cas9功能缺失筛选,发现IL-1R信号通过NFKBIZ-IL-17F-MAPK轴自分泌环路维持PD-L1表达并诱导免疫抑制微环境,药物抑制IL-1R信号可增强CD30特异性CAR疗法在体外及ALCL异种移植模型中的抗肿瘤活性。
要点
- IL-1R信号驱动NFKBIZ-IL-17F-MAPK轴,经自分泌环路维持PD-L1表达。
- NFKBIZ是调控该免疫抑制程序的上游核心转录调节因子。
- 药物抑制IL-1R信号可增强CD30特异性CAR疗法的抗肿瘤活性。
核心结论
- 研究揭示ALCL免疫抵抗的新机制,并提出IL-1R阻断作为改善CAR免疫治疗的组合策略。
研究设计与样本
- 采用CD30特异性CAR工程化自然杀伤(CAR-NK)细胞进行全基因组CRISPR-Cas9功能缺失筛选,并辅以PD-L1调节因子筛选。
主要发现
- IL-1R信号在ALK⁺和ALK⁻ ALCL中均调节CAR治疗疗效。
- IL-1R信号驱动NFKBIZ-IL-17F-MAPK轴,通过自分泌环路维持PD-L1表达,并诱导促炎细胞因子和趋化因子。
- NFKBIZ(IκBζ)作为上游核心转录调节因子协调该免疫抑制程序。
- 药物抑制IL-1R信号在体外和ALCL异种移植模型中均显著增强CD30特异性CAR疗法的抗肿瘤活性。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Anaplastic large cell lymphoma (ALCL), an aggressive T-cell malignancy, is marked by elevated expression of CD30 and the immune checkpoint molecule PD-L1. While CD30-directed chimeric antigen receptor (CAR) therapies have demonstrated clinical promise, therapeutic resistance remains a major hurdle. Here, we conducted integrated genome-wide CRISPR-Cas9 loss-of-function screens using CD30-specific CAR-engineered natural killer (CAR-NK) cells, alongside a complementary PD-L1 regulator screen, and uncovered a critical role for interleukin-1 receptor (IL-1R) signaling in modulating CAR therapy efficacy in both ALK⁺ and ALK⁻ ALCL. Mechanistically, IL-1R signaling drives an NFKBIZ - IL-17F - MAPK axis that sustains PD-L1 expression via an autocrine loop, while simultaneously inducing proinflammatory cytokines and chemokines that reinforce immune evasion and shape an immunosuppressive tumor microenvironment. Notably, NFKBIZ (IκBζ) emerges as a central transcriptional regulator orchestrating this immune suppression program upstream of IL-17F. Importantly, pharmacologic inhibition of IL-1R signaling significantly enhances the antitumor activity of CD30-specific CAR therapies both in vitro and in ALCL xenograft models. Collectively, our findings uncover a novel mechanism of immune resistance and nominate IL-1R blockade as a promising combinatorial strategy to improve CAR-based immunotherapy in ALCL.
引用
- Wei W, Song Z, Wang Y, et al. The IL-1R and NFKBIZ pathway mediates immunoregulatory responses and immunotherapy efficacy in anaplastic large cell lymphoma. Leukemia. 2025. PMID: 41225182. doi:10.1038/s41375-025-02809-x
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。